Actinogen Medical Limited
Actinogen Medical Limited, a biotechnology company, develops therapies for neurological and neuropsychiatric diseases associated with dysregulated brain cortisol in Australia. It develops Xanamem, an oral medication and inhibitor of the 11ß-HSD1 enzyme that achieves target engagement in the brain for the treatment of Alzheimer's disease, major depressive disorder, fragile x syndrome, and other ne… Read more
Actinogen Medical Limited (ATGGF) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of June 2025: -0.507x
Based on the latest financial reports, Actinogen Medical Limited (ATGGF) has a cash flow conversion efficiency ratio of -0.507x as of June 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-9.29 Million) by net assets ($18.34 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Actinogen Medical Limited - Cash Flow Conversion Efficiency Trend (2008–2025)
This chart illustrates how Actinogen Medical Limited's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Actinogen Medical Limited Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Actinogen Medical Limited ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Katahdin Bankshares Corp
OTCQX:KTHN
|
0.083x |
|
Leenos Corp
KQ:039980
|
-0.007x |
|
Geox S.p.A
PINK:GXSBF
|
0.013x |
|
WESTERN INV.CO.OF CANADA
F:1KC
|
N/A |
|
HF FOODS GRP INC.DL-0001
F:3GX
|
N/A |
|
Som Distilleries & Breweries Limited
NSE:SDBL
|
0.104x |
|
Bogazici Beton Sanayi ve Ticaret AS
IS:BOBET
|
0.087x |
|
Long Bon International Co Ltd
TW:2514
|
0.008x |
Annual Cash Flow Conversion Efficiency for Actinogen Medical Limited (2008–2025)
The table below shows the annual cash flow conversion efficiency of Actinogen Medical Limited from 2008 to 2025.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-06-30 | $18.34 Million | $-7.56 Million | -0.412x | +52.12% |
| 2024-06-30 | $19.70 Million | $-16.95 Million | -0.861x | -32.65% |
| 2023-06-30 | $13.41 Million | $-8.70 Million | -0.649x | -48.20% |
| 2022-06-30 | $21.74 Million | $-9.52 Million | -0.438x | -343.34% |
| 2021-06-30 | $17.46 Million | $-1.72 Million | -0.099x | +62.35% |
| 2020-06-30 | $10.89 Million | $-2.86 Million | -0.262x | +60.87% |
| 2019-06-30 | $15.66 Million | $-10.50 Million | -0.670x | -46.20% |
| 2018-06-30 | $17.26 Million | $-7.91 Million | -0.458x | -287.20% |
| 2017-06-30 | $9.37 Million | $-1.11 Million | -0.118x | +71.51% |
| 2016-06-30 | $12.13 Million | $-5.04 Million | -0.416x | -71.57% |
| 2015-06-30 | $15.36 Million | $-3.72 Million | -0.242x | +32.96% |
| 2014-06-30 | $1.21 Million | $-437.84K | -0.361x | +44.08% |
| 2013-06-30 | $194.35K | $-125.56K | -0.646x | +72.79% |
| 2012-06-30 | $346.99K | $-823.94K | -2.375x | -208.31% |
| 2011-06-30 | $1.05 Million | $-805.70K | -0.770x | -23.70% |
| 2010-06-30 | $1.17 Million | $-727.37K | -0.623x | -116.57% |
| 2009-06-30 | $1.90 Million | $-546.87K | -0.287x | -106.93% |
| 2008-06-30 | $2.86 Million | $-397.22K | -0.139x | -- |